Showing 1491-1500 of 2149 results for "".
- Valeant to Sell Obagi Medical Products Business for $190 Mhttps://practicaldermatology.com/news/valeant-to-sell-obagi-medical-products-business-for-190-m/2458117/Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic ma
- Patent Challenge Filed for Generic Version Of Soolantra Creamhttps://practicaldermatology.com/news/patent-challenge-filed-for-generic-version-of-soolantra-cream/2458120/Perrigo Company plc's subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the FDA for a generic version of Soolantra® (ivermectin) cream, 1%. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a
- Survey: Despite Knowledge, Parents Don't Drive Kids' Sunscreen Usehttps://practicaldermatology.com/news/survey-despite-knowledge-parents-dont-drive-kids-sunscreen-use/2458142/According to a new Neutrogena Survey conducted online by Harris Poll, more than 4 in 5 parents of children under 18 years old say their children do not wear sunscreen on a daily basis— despite over 9 in 10 Americans believing sunscreen is important for protecting a child’s health.
- Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clueshttps://practicaldermatology.com/news/largest-psoriasis-meta-analysis-to-date-yields-new-genetic-clues/2458176/A new meta -analysis identifies 16 additional genetic markers that may help researchers get closer to understanding how — and why — psoriasis develops. University of Michigan researchers, working with partners across the globe, published the work in
- Valeant Appoints New Dermatology and Corporate Communications Leadership Membershttps://practicaldermatology.com/news/valeant-appoints-new-dermatology-and-corporate-communications-leadership-members/2458192/Valeant Pharmaceuticals International, Inc. added new members to the dermatology leadership team—Michael McMyne is the new Vice President of Sales and Stacey Williams is the new Vice President of Marketing. Additionally, the comp
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- Modernizing Medicine and Galderma Team Up to Offer Integrated OTC eCommerce Platformhttps://practicaldermatology.com/news/modernizing-medicine-and-galderma-team-up-to-offer-integrated-otc-ecommerce-platform/2458264/Specialty-specific health information technology company Modernizing Medicine, Inc. and Galderma Laboratories, L.P. are collaborating to deliver new capabilities in support of improved patient experiences and outcomes through healthcare provider recommended over-
- Sun Pharma Introduces Leave Acne Behind Patient Initiativehttps://practicaldermatology.com/news/sun-pharma-introduces-leave-acne-behind-patient-initiative/2458310/Sun Pharma introudced a new initiative— “Leave Acne Behind™" — to educate patients and create awareness of severe recalcitrant nodular acne (SRNA). Sun Pharma reports that out of all of the prescription- treated acne cases today, 20 percent represent severe acne condi
- Galderma's Restylane Refyne and Restylane Defyne Fillers FDA Approved for “Laugh Lines”https://practicaldermatology.com/news/galdermas-restylane-refyne-and-restylane-defyne-fillers-fda-approved-for-laugh-lines/2458349/The FDA approved two new products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21—Galderma's Restylane Refyne and Restylane Defyne. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkl
- Cetaphil® Marks Fifth Year of Support for CSDF and Camp Wonderhttps://practicaldermatology.com/news/cetaphil-marks-fifth-year-of-support-for-csdf-and-camp-wonder/2458452/Galderma Laboratories, L.P., makers of Cetaphil, is celebrating the fifth consecutive year of its "Meaningphil™" partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder.</